SOPHiA GENETICS (SOPH) Hisse Özeti
SOPHiA GENETICS SA, sağlık hizmetleri alanında bulut tabanlı bir yazılım teknolojisi şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
SOPH Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SOPHiA GENETICS SA Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$8.28 |
| 52 Haftanın En Yüksek Seviyesi | US$8.31 |
| 52 Haftanın En Düşük Seviyesi | US$3.10 |
| Beta | 0.92 |
| 1 Aylık Değişim | 30.81% |
| 3 Aylık Değişim | 63.96% |
| 1 Yıllık Değişim | 131.28% |
| 3 Yıllık Değişim | 249.37% |
| 5 Yıllık Değişim | -54.38% |
| Halka arzdan bu yana değişim | -50.60% |
Son Haberler & Güncellemeler
Recent updates
Anlatı Güncellemesi • Aug 18
SOPH: Astrazeneca Partnerships And AI Platform Will Drive Future Oncology Opportunity
Analysts have lifted the SOPHiA GENETICS analyst price target from $12 to $14, citing recent Street research that highlights stronger Q2 results, a raised outlook, major AstraZeneca and companion diagnostics partnerships, growing U.S. adoption, and recurring, usage based revenue streams across clinical and biopharma markets as key supports for this updated view. Analyst Commentary Bullish analysts see SOPHiA GENETICS as a company that is executing on its plan, with recent research pointing to what they view as strong Q2 results, a raised outlook, and expanding commercial traction.Anlatı Güncellemesi • Aug 04
SOPH: AI Multimodal Data Platform Will Drive Future Oncology Opportunity
Analysts have raised their price target on SOPHiA GENETICS from $9 to $12, citing the company's AI-driven use of multimodal genomic and clinical data, its recurring usage-based revenue model across clinical and biopharma customers, and its exposure to an estimated $40 billion market. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS filed and then completed a follow on equity offering of common stock, raising US$49.9985 million through 10,526,000 shares priced at US$4.75 per share with a US$0.285 discount per share.
Anlatı Güncellemesi • Jul 21
SOPH: AI Usage Model And NHS Rollout Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS stock to $12, citing the company’s AI-driven, usage-based revenue model across clinical and biopharma customers, as well as its exposure to an estimated $40 billion addressable market, as key factors supporting the updated valuation and fair value assumptions. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS completed a follow on equity offering of 10,526,000 common shares at US$4.75 per share, raising approximately US$49.9985 million.Seeking Alpha • Jun 18
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Summary SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint. Management targets adjusted EBITDA breakeven by end-2026 and profitability in 2027, supported by cost discipline, new high-value applications, and expanding customer adoption. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 15
SOPH: New Partnerships And Ai Collaboration Will Support Future Precision Oncology
Analysts have increased their price target on SOPHiA GENETICS by $1, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture that aims to combine Memorial Sloan Kettering Cancer Center clinical data with the SOPHiA DDM Ai platform for multimodal precision oncology research and deployment.Anlatı Güncellemesi • Jun 01
SOPH: NHS Liquid Biopsy Rollout Will Support Future Upside Potential
Analysts have lifted their price target on SOPHiA GENETICS by $1, citing updated models that reflect a lower discount rate, adjusted revenue growth and profit margin assumptions, and a revised future P/E estimate. What's in the News SOPHiA GENETICS partnered with Synnovis, a leading pathology provider in England, to roll out liquid biopsy testing for lung and breast cancer patients across the U.K. under NHS England's blood test first program, using the MSK-ACCESS® test powered by SOPHiA DDM™.Anlatı Güncellemesi • May 15
SOPH: New NHS Partnerships Will Support Future Precision Oncology Adoption
Analysts recently lifted their price target on SOPHiA GENETICS by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework for the stock. Analyst Commentary Recent research has framed the updated price target as a fine tuning of prior assumptions rather than a major shift in conviction.Anlatı Güncellemesi • Apr 24
SOPH: Higher Future P/E Assumptions Will Support Upside Potential
Analysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms. Analyst Commentary Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS.Anlatı Güncellemesi • Apr 09
SOPH: New U.S. Health System Partnerships Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS by $1, reflecting updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E as highlighted in recent Street research. Analyst Commentary Recent Street research around SOPHiA GENETICS points to a more cautious tone, even as price targets are adjusted to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples.Anlatı Güncellemesi • Mar 26
SOPH: Higher Future P/E And New U.S. Partnerships Will Support Upside
Analysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.Anlatı Güncellemesi • Mar 11
SOPH: New US Health System Deals Will Support Future Upside
Analysts lifted their fair value estimate for SOPHiA GENETICS by $1.00 to $7.00, citing updated assumptions for growth, profitability, and future P/E that align with the recent $1 upward move in the Street price target. Analyst Commentary While the latest fair value move to $7.00 lines up with the recent Street price target adjustment, not everyone is leaning positive.Anlatı Güncellemesi • Feb 25
SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform Adoption
Analysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x. Analyst Commentary Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x.Anlatı Güncellemesi • Feb 10
SOPH: Oncology Collaboration And New Leadership Will Support Future Platform Adoption
Analysts have nudged their price target on SOPHiA GENETICS higher by about US$1, reflecting updated views on the company that are consistent with recent Street research commentary. Analyst Commentary Bullish Takeaways Bullish analysts connect the roughly US$1 price target adjustment to refreshed expectations on how SOPHiA GENETICS can execute on its roadmap.Anlatı Güncellemesi • Jan 27
SOPH: Higher Price Work Will Highlight Expanding Oncology Collaborations
Analysts have increased their price target on SOPHiA GENETICS by US$1, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lifting their fair value assumptions by US$1 are essentially fine tuning how they see SOPHiA GENETICS balancing growth potential, execution risk, and valuation multiples such as P/E over time.Analiz Makalesi • Sep 30
Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% Higher
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shares have continued their recent momentum with a 28% gain in the last month alone...Analiz Makalesi • Aug 08
Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter Results
NasdaqGS:SOPH 1 Year Share Price vs Fair Value Explore SOPHiA GENETICS's Fair Values from the Community and select...Anlatı Güncellemesi • Aug 06
Precision Medicine Advances Will Transform Global Healthcare Analytics
SOPHiA GENETICS' consensus price target has been reduced to $6.75, primarily reflecting lowered revenue growth expectations despite a modest improvement in net profit margin. What's in the News SOPHiA GENETICS reiterated its full-year 2025 revenue guidance of $72 million to $76 million.Analiz Makalesi • Jul 10
Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders have had their patience rewarded with a 29% share price jump in the...
Yeni Anlatı • Apr 02
Expedited Implementation And New US Signings Will Boost Future Impact
Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share.Analiz Makalesi • Mar 20
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders won't be pleased to see that the share price has had a very rough...Analiz Makalesi • Jan 10
Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Analiz Makalesi • Oct 03
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Aug 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Shareholders in SOPHiA GENETICS SA ( NASDAQ:SOPH ) had a terrible week, as shares crashed 25% to US$3.36 in the week...Analiz Makalesi • Aug 08
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
When you see that almost half of the companies in the Healthcare Services industry in the United States have...Hissedar Getirileri
| SOPH | US Healthcare Services | US Pazar | |
|---|---|---|---|
| 7D | 9.4% | 2.8% | -0.3% |
| 1Y | 131.3% | -22.4% | 19.9% |
Getiri vs. Endüstri: SOPH geçen yıl % -22.4 oranında getiri sağlayan US Healthcare Services sektörünü aştı.
Getiri vs Piyasa: SOPH geçen yıl % 19.9 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| SOPH volatility | |
|---|---|
| SOPH Average Weekly Movement | 10.2% |
| Healthcare Services Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: SOPH son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SOPH 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2011 | 415 | Ross Muken | www.sophiagenetics.com |
SOPHiA GENETICS SA, sağlık sektöründe bulut tabanlı bir yazılım teknolojisi şirketi olarak faaliyet göstermektedir. Şirket, çok modlu veri kümeleri ve tanı yöntemlerinden verileri analiz etmek ve içgörüler elde etmek için tasarlanmış bulut tabanlı bir yazılım platformu olan SOPHiA DDM platformunu sunmaktadır. SOPHiA DDM platformu ve ilgili çözümleri, uygulamaları, ürünleri ve hizmetleri, şirketin kendi satış ekibinin yanı sıra İsviçre, Fransa, İtalya, Avrupa’nın geri kalanı, Kuzey Amerika, Amerika Birleşik Devletleri, Latin Amerika ve Asya-Pasifik bölgelerindeki distribütörler ve sektördeki iş ortakları aracılığıyla hastaneler, laboratuvarlar ve biyofarmasötik şirketleri tarafından kullanılmaktadır.
SOPHiA GENETICS SA Temel Bilgiler Özeti
| SOPH temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$648.67m |
| Kazançlar(TTM) | -US$80.88m |
| Gelir(TTM) | US$86.17m |
8.2x
P/S Oranı-8.7x
F/K OranıSOPH aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SOPH gelir tablosu (TTM) | |
|---|---|
| Gelir | US$86.17m |
| Gelir Maliyeti | US$28.76m |
| Brüt Kâr | US$57.41m |
| Diğer Giderler | US$138.29m |
| Kazançlar | -US$80.88m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.95 |
| Brüt Marj | 66.63% |
| Net Kâr Marjı | -93.86% |
| Borç/Özkaynak Oranı | 57.7% |
SOPH uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/19 00:09 |
| Gün Sonu Hisse Fiyatı | 2026/08/19 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
SOPHiA GENETICS SA 7 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |